ABIO vs. AWH, ICCC, VNRX, TKNO, OCX, CDIO, TRIB, ACHV, ELDN, and ZEPP
Should you be buying ARCA biopharma stock or one of its competitors? The main competitors of ARCA biopharma include Aspira Women's Health (AWH), ImmuCell (ICCC), VolitionRx (VNRX), Alpha Teknova (TKNO), OncoCyte (OCX), Cardio Diagnostics (CDIO), Trinity Biotech (TRIB), Achieve Life Sciences (ACHV), Eledon Pharmaceuticals (ELDN), and Zepp Health (ZEPP). These companies are all part of the "medical" sector.
Aspira Women's Health (NASDAQ:AWH) and ARCA biopharma (NASDAQ:ABIO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.
In the previous week, ARCA biopharma had 6 more articles in the media than Aspira Women's Health. MarketBeat recorded 8 mentions for ARCA biopharma and 2 mentions for Aspira Women's Health. Aspira Women's Health's average media sentiment score of 0.28 beat ARCA biopharma's score of -0.50 indicating that ARCA biopharma is being referred to more favorably in the news media.
ARCA biopharma has a net margin of 0.00% compared to ARCA biopharma's net margin of -176.74%. Aspira Women's Health's return on equity of -15.76% beat ARCA biopharma's return on equity.
ARCA biopharma has lower revenue, but higher earnings than Aspira Women's Health. ARCA biopharma is trading at a lower price-to-earnings ratio than Aspira Women's Health, indicating that it is currently the more affordable of the two stocks.
ARCA biopharma received 110 more outperform votes than Aspira Women's Health when rated by MarketBeat users. Likewise, 42.56% of users gave ARCA biopharma an outperform vote while only 30.23% of users gave Aspira Women's Health an outperform vote.
Aspira Women's Health currently has a consensus price target of $4.45, indicating a potential upside of 33.77%. Given ARCA biopharma's higher possible upside, analysts plainly believe Aspira Women's Health is more favorable than ARCA biopharma.
Aspira Women's Health has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, ARCA biopharma has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.
12.2% of Aspira Women's Health shares are owned by institutional investors. Comparatively, 56.4% of ARCA biopharma shares are owned by institutional investors. 4.3% of Aspira Women's Health shares are owned by company insiders. Comparatively, 30.9% of ARCA biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
ARCA biopharma beats Aspira Women's Health on 11 of the 16 factors compared between the two stocks.
Get ARCA biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ARCA biopharma Competitors List
Related Companies and Tools
